Pharmaceutical equivalent 5-aminolevulinic acid fluorescence guided resection of central nervous system tumors: feasibility, safeness and cost-benefit considerations
Journal of Neuro-Oncology · 2024
DOI: 10.1007/s11060-024-04698-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Erasmo Barros da Silva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurooncology, Department of Neurosurgery, Instituto de Neurologia de Curitiba, Rua Jeremias Maciel Perretto, 300 - Campo Comprido, 81210…. Hauptthemen laut MEDLINE: Aminolevulinic Acid, Cost-Benefit Analysis, Feasibility Studies, Central Nervous System Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: 5-aminolevulinic acid (5-ALA) fluorescence-guided resection (FGR) has been an essential tool in the 'standard of care' of malignant gliomas. Over the last two decades, its indications have been extended to other neoplasms, such as metastases and meningiomas. However, its availability and cost-benefit still pose a challenge for widespread use. The present article reports a retrospective series of 707 cases of central nervous system (CNS) tumors submitted to FGR with pharmacological equivalent 5-ALA and discusses financial implications, feasibility and safeness. METHODS: From December 2015 to February 2024, a retrospective single institution series of 707 cases of 5-ALA FGR were analyzed. Age, gender, 5-ALA dosage, intraoperative fluorescence finding, diagnosis and adverse effects were recorded. Financial impact in the surgical treatment cost were also reported. RESULTS: there was an additional cost estimated in $300 dollars for each case, increasing from 2,37 to 3,28% of the total hospitalization cost. There were 19 (2,69%) cases of asymptomatic photosensitive reaction and 2 (0,28%) cases of photosensitive reaction requiring symptomatic treatment. 1 (0,14%) patient had a cutaneous rash sustained for up to 10 days. No other complications related to the method were evident. In 3 (0,42%) cases of patients with intracranial hypertension, there was vomiting after administration. CONCLUSION: FGR with pharmacological equivalent 5-ALA can be considered safe and efficient and incorporates a small increase in hospital expenses. It constitutes a reliable solution in avoiding prohibitive costs worldwide, especially in countries where commercial 5-ALA is unavailable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurooncology, Department of Neurosurgery, Instituto de Neurologia de Curitiba, Rua Jeremias Maciel Perretto, 300 - Campo Comprido, 81210-310, Curitiba, PR, Brazil. erasmo-inc@uol.com.br.
- Division of Neurooncology, Department of Neurosurgery, Instituto de Neurologia de Curitiba, Rua Jeremias Maciel Perretto, 300 - Campo Comprido, 81210-310, Curitiba, PR, Brazil.
Zitieren
APA
da Silva, E. B., Ramina, R., Novak Filho, J. L., Jung, G. S., Bornancin, G. X., & Neto, M. C. (2024). Pharmaceutical equivalent 5-aminolevulinic acid fluorescence guided resection of central nervous system tumors: feasibility, safeness and cost-benefit considerations. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04698-z
Vancouver
da Silva EB, Ramina R, Novak Filho JL, Jung GS, Bornancin GX, Neto MC. Pharmaceutical equivalent 5-aminolevulinic acid fluorescence guided resection of central nervous system tumors: feasibility, safeness and cost-benefit considerations. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04698-z
BibTeX
@article{daSilva2024,
author = {da Silva, Erasmo Barros and Ramina, Ricardo and Novak Filho, Jorge Luis and Jung, Gustavo Simiano and Bornancin, Giulia Xavier and Neto, Maurício Coelho},
title = {Pharmaceutical equivalent 5-aminolevulinic acid fluorescence guided resection of central nervous system tumors: feasibility, safeness and cost-benefit considerations},
journal = {Journal of Neuro-Oncology},
year = {2024},
doi = {10.1007/s11060-024-04698-z}
}
EUVIMED